FDA Guides ANDA Sponsors On Being “Easily Correctable”
Executive Summary
Draft guidance defines “easily correctable deficiencies” as those requiring a “modest expenditure of FDA resources and do not require a goal date extension, but a late response still could force an adjustment.
You may also be interested in...
ANDA Amendments Cannot Get Mid-Review Communications Like Full Applications - FDA
Generic industry officials ask that information requests and discipline review letters be issued during ANDA amendment assessments, but the US agency says they are not allowed in GDUFA II.
ANDA Amendments Cannot Get Mid-Review Communications Like Full Applications - FDA
Generic industry officials ask that information requests and discipline review letters be issued during ANDA amendment assessments, but the US agency says they are not allowed in GDUFA II.
ANDA Submissions Continue Yo-Yo Pattern, Unlike Approvals
After spike in March, generic drug application submissions drop 62% in April, while approval volume remains at monthly average.